Skip to content

Search

Showing results for "Study of bullying"

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.

Fiona Stanley Circle

Make improving child health your legacy, by including The Kids Research Institute Australia in your will.

Web/Database Developer

The Opportunity We have a great opportunity for an enthusiastic individual with a breadth of technical skills to focus on the development of data

Neil

Neil Dad to five biological children and five long-term foster kids. Project community member, trial participant, advocate. Of my desire to find out

Bright Blue

Bright Blue The Police Commissioner's Fund for Sick Kids has generously outfitted the The Kids brain tumour lab with a cancer analysis suite.